Neoadjuvant Therapy of SBRT Sequencial With Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC Patients(neoR-TORCH)

This study tests a pre-surgery treatment approach for early to locally advanced non-small cell lung cancer (NSCLC) that combines targeted radiation (SBRT) with immunotherapy (toripalimab) and chemotherapy before surgical removal, to try to shrink the tumor and improve cure rates. **You may be eligible if...** - You are between 18 and 75 years old - You have untreated, resectable (surgically removable) Stage II, IIIA, or IIIB (N2) NSCLC confirmed by biopsy - Your cancer does not have EGFR or ALK gene mutations - Your lung function is sufficient for surgery in your doctor's judgment - You have adequate blood counts and organ function **You may NOT be eligible if...** - Your cancer is locally advanced and cannot be surgically removed - You have NSCLC in the top of the lung (superior sulcus), large cell neuroendocrine carcinoma, or sarcomatoid tumors - Your cancer has EGFR or ALK mutations (other targeted therapies are more appropriate) - You are pregnant Talk to your doctor to see if this trial is right for you.